Collegium Pharmaceutical, Inc. Receives FDA Fast Track Designation for Tamper Resistant, Chronic Pain Product, COL-172
6/10/2010 9:32:56 AM
CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of COL-172 for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. COL-172, a tamper resistant, extended release oral opioid formulation, is the Company’s second product candidate incorporating its proprietary DETERx™ technology for which it has filed an IND application. The Company’s lead product candidate, COL-003, is currently in late stage clinical development and has also been granted Fast Track Designation by the FDA.
comments powered by